scPharmaceuticals Inc. (SCPH) News
Filter SCPH News Items
SCPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SCPH News From Around the Web
Below are the latest news stories about SCPHARMACEUTICALS INC that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2023 Earnings Call TranscriptscPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2023 Earnings Call Transcript November 8, 2023 scPharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.36. Operator: Thank you for standing by. This is the conference operator. Welcome to the scPharmaceuticals Third Quarter 2023 Earnings Conference Call. As a reminder, all participants are in listen-only mode […] |
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateGenerated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduc |
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss the financial res |
scPharmaceuticals to Participate in Two Upcoming Investor ConferencesBURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences. Event: Jefferies London Healthcare ConferenceTuesday, November 14, 2023Fireside chat |
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 47%While scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders are probably generally happy, the stock hasn't had... |
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate |
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth InitiativesCompany advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX into chronic kidney disease (CKD) BURLINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the |
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceBURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 |
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue EstimatesscPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateGenerated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today, Thursday, August 10, at 4:30pm ET BURLINGTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce |